Nasseo moves into the Fast Lane
Nasseo, Inc. is a start-up medical device company developing an implant surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Over the past 18 months the company has achieved very impressive milestones and is in the Fast Lane to delivering a new platform technology that benefits patients in several compelling markets. In 2013 NASSEO was accepted into the BioInspire Medical Device accelerator in Peoria, AZ. In addition to mentoring and support, NASSEO received a $300,000 investment of seed funding from the highly competitive program. NASSEO was also named the 2013 Innovation Challenge Winner by the Arizona Commerce Authority (ACA) in its spring Arizona Innovation Challenge securing $250,000 for the commercialization of its first product, the TiArray™ Dental Implant which received FDA approval in 2013.
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. The company was formed in 2001 by world-renowned heart surgeon Jack G. Copeland, MD, interventional cardiologist Marvin J. Slepian, MD, and biomedical engineer Richard G. Smith, MSEE, CCE, to commercialize the SynCardia temporary Total Artificial Heart .
Building a Medical School
A dream come true for downtown Phoenix; Building a new medical school For six local doctors, the creation of what is now one of the newest medical colleges in the nation seemed a distant dream. These seasoned professionals have invested many years, personal and professional commitment, expertise and downright tenacity, to make this campus and this college a reality. All contributed from their respective fields and their respective hospitals. All were teachers and saw the need for the development of the University of Arizona College of Medicine - Phoenix. Read more at: http://phoenixmed.arizona.edu
The Greener Side of Bio
AZBio Board Chair and Co-Founder of Algae Biosciences, Glen Galster , moderates this panel discussion on the state of Arizona's green bio industry amd whwere it's going with Leif P. Christoffersen , Director of Biomass Integration, Yulex Corporation . Leif is responsible for advancing Yulex’s energy, efficiency and biomass initiatives. Prior to Yulex, Christoffersen played a key role in establishing the E.O. Wilson Biodiversity Foundation (EOWBF) with whom he maintains an active advisory role. He also spent over five years at the Diversa Corporation (Verenium Corporation and BP Biofuels), where he managed bioprospecting collaborations, as well as managed Diversa’s grants program, coordinated their scientific advisory board, and supported their international business development efforts. Christoffersen has also served as a climate change adviser to the Executive Director of UNEP at COP1 and COP2 of the Climate Change Convention (UNFCCC). At the start of his career, he worked with subsistence farmers in Costa Rica and Kenya to support and promote agroforestry practices, which included setting up exportation of organic produce. Christoffersen holds a degree from Hobart College (BA, Economics) and the University of California, San Diego (MBA, Rady School of Management). Ben Cloud , President and CEO, Phyco Biosciences, Inc ., brings over 30 years of experience as a farmer and farmland developer with operations in Arizona and Southern California. His significant experience in production agriculture including drip-micro irrigation systems and design, cropping systems, processing and marketing have contributed to the development of the Phyco production platform and business approach (To learn more, click here .) and Josh Hottenstein of the Cleantech Open
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches. Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award .
Ground Broken for University of Arizona Cancer Center in Phoenix
Ground Broken for University of Arizona Cancer Center in Phoenix Ground was officially broken on the new University of Arizona Cancer Center (UACC) at St. Joseph's Hospital and Medical Center/Dignity Health outpatient facility in downtown Phoenix in February, 2013. Located on the Phoenix Biomedical Campus at 625 N. Sixth St., on the northwest corner of Fillmore and Seventh streets, the center is expected to be open in 2015. Follow the project's construction progress at www.phoenixcancercenter.org
Tying it all together for start up success
Alan Nelson is heading the Predictive Health Analytics Initiative that aims to change the paradigm in healthcare from treating late stage disease to early diagnosis and preventive therapies that are cost-effective. He served as the Executive Director of the Biodesign Institute at ASU and holds professorships in Bioengineering and physics. He is the founder and CEO of three companies, the most recent being VisionGate, the innovator of the LuCED lung cancer early detection test. VisionGate was awarded the start-up of the year award at the recent Governors’ celebration of innovation. Alan has a PhD in Biophysics from Berkeley, holds 66 issued patents, and has published over 100 scholarly papers in biomedical imaging.
From Discovery to Development to Delivery: Biodesign
Raymond N. DuBois, MD, PhD , executive director of The Biodesign Institute at Arizona State University explains the history and the value of biodesign and shares a look at the bioinspired, use inspired, research being done by innovative teams at The Biodesign Institute in their three focus areas of health, energy, and security.